GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Effective Interest Rate on Debt %

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Effective Interest Rate on Debt % : 0.00% (As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Algernon Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Feb. 2024 was $0.00 Mil. Algernon Pharmaceuticals's average total debt for the quarter that ended in Feb. 2024 was $0.00 Mil. Therefore, Algernon Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2024 was N/A%.


Algernon Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Algernon Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Effective Interest Rate on Debt % Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only - - - - -

Algernon Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Algernon Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Algernon Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Effective Interest Rate on Debt % falls into.



Algernon Pharmaceuticals Effective Interest Rate on Debt % Calculation

Algernon Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Aug. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Aug. 2022 )+Total Debt  (A: Aug. 2023 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

Algernon Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Nov. 2023 )+Total Debt  (Q: Feb. 2024 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Feb. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Algernon Pharmaceuticals  (OTCPK:AGNPF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Algernon Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

By Stock market mentor Stock market mentor 01-11-2023

Algernon Pharmaceuticals Announces Closing of Rights Offering

By sperokesalga sperokesalga 05-05-2023

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

By sperokesalga sperokesalga 03-01-2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

By Stock market mentor Stock market mentor 01-17-2023